Abbott Laboratories
ABT· NYSE
ABTAbbott Laboratories
Filed Feb 18, 2022 · 10-K · 49 days after period end · 0001104659-22-025141
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $11.47B | $10.70B | $8.31B | $7.77B |
| Net Income | $1.99B | $2.16B | $1.05B | $654.00M |
| EPS Diluted | — | — | $0.59 | $0.37 |
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Feb 18, 2022 · 49 d after period end
